Paper32423643
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
Pertejo-Fernandez A and 7 others. Lung Cancer, 2020. Cited by 39 papers, by iCite.
Cite this record
ConductScience Library. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Papers, record 32423643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32423643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Hepatitis B | Major topic |
| Hepatitis C | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Retrospective Studies |
Source PubMed
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42281419 | KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA). | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/42281419 | PubMed |
| 42125666 | Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk. | Front Immunol | 2026 | https://conductscience.org/library/papers/42125666 | PubMed |
| 41606625 | Cross-domain neural collaborative filtering for personalized herbal prescription recommendation. | Chin Med | 2026 | https://conductscience.org/library/papers/41606625 | PubMed |
| 40897718 | Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors. | NPJ Biofilms Microbiomes | 2025 | https://conductscience.org/library/papers/40897718 | PubMed |
| 40841937 | Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40841937 | PubMed |
| 38721408 | Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2024 | https://conductscience.org/library/papers/38721408 | PubMed |
| 38161553 | The Missed Opportunity: HIV, Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) Positive Patients in Neoadjuvant and Perioperative Immunotherapy Clinical Trials for Lung Cancer. | Cureus | 2023 | https://conductscience.org/library/papers/38161553 | PubMed |
| 37736699 | Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. | Infect Dis Poverty | 2023 | https://conductscience.org/library/papers/37736699 | PubMed |
| 36936956 | Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. | Front Immunol | 2023 | https://conductscience.org/library/papers/36936956 | PubMed |
| 36871274 | Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004). | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/36871274 | PubMed |
| 36762057 | Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV). | Transl Lung Cancer Res | 2023 | https://conductscience.org/library/papers/36762057 | PubMed |
| 36647390 | Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. | J Oncol | 2023 | https://conductscience.org/library/papers/36647390 | PubMed |
| 36484006 | Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review. | J Cancer | 2022 | https://conductscience.org/library/papers/36484006 | PubMed |
| 36425873 | An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/36425873 | PubMed |
| 35938033 | Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report. | Front Genet | 2022 | https://conductscience.org/library/papers/35938033 | PubMed |
| 35767193 | Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/35767193 | PubMed |
| 35663533 | Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy. | J Immunother Precis Oncol | 2021 | https://conductscience.org/library/papers/35663533 | PubMed |
| 35601125 | Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. | JGH Open | 2022 | https://conductscience.org/library/papers/35601125 | PubMed |
| 35256688 | Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment. | Sci Rep | 2022 | https://conductscience.org/library/papers/35256688 | PubMed |
| 34607905 | Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. | Thorax | 2022 | https://conductscience.org/library/papers/34607905 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32423643
GET https://conductscience.org/api/papers/v1/32423643/cited_by?page=2